SIGNIA
SIGNIA: An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SIGNIA project word cloud
Explore the words cloud of the SIGNIA project. It provides you a very rough idea of what is the project "SIGNIA" about.
Project "SIGNIA" data sheet
The following table provides information about the project.
| Coordinator |
SIGNIA THERAPEUTICS
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | https://signiatherapeutics.com/en/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2018-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | SIGNIA THERAPEUTICS | FR (VILLEURBANNE) | coordinator | 50˙000.00 |
Map
Project objective
The economic and social burden of infections is being enhanced by the emergence of drug-resistant pathogens. This phenomenon is outpacing the industry’s capacity for drug discovery and development. Antimicrobial resistance is costing the EU today €1.5 billion and 25,000 deaths annually. Developing de novo classical drugs is very costly and time consuming, and for every new drug released a resistant strain has rapidly emerged. This paradigm is hindering our ability to respond to outbreaks. Among causative organisms, viruses pose a major threat, being responsible for the outbreaks impacting the world in the past decade (SARS, Influenza A, MERS, etc). Although some antivirals have been developed for them, they lose their efficacy rapidly due to the high mutation rate of viruses, which alters the antigenic features originally used to develop the drug. Thus, there is an urgent need for novel discovery methods that allow to accelerate the development of broad-spectrum and mutability-independent antimicrobials. In response, Signia Therapeutics has developed and validated a drug discovery platform for fast identification of compounds with antimicrobial activity. Instead of selecting drugs that target pathogen determinants, it selects drugs that target determinants of the infected cell. This method offers key advantages: i) avoids the impact of microbe intrinsic mutability; ii) broad spectrum drugs can be identified. Since the platform seeks for antimicrobial applications among drugs already commercialized (repurposing) and among pharma libraries (recycling), drug discovery becomes faster, safer and cost-efficient. Having reached the functional stage (TRL6), this project encloses the roadmap to finalise the platform’s development and its preparation for market. Once completed, this project will have huge impacts for society (better management of infections and preparedness against outbreaks), and for our company (expected ROI of €2.1 from this project after 5 years).
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIGNIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SIGNIA" are provided by the European Opendata Portal: CORDIS opendata.